Specialists and strong fundamentals must carry the sector in 3Q19

Heading into the third quarter, specialist biotech investors are in the driver’s seat, and their stances on whether to trim or spend in the down market are split.

After recovering at the start of the year from the correction territory of 4Q18, the biotech sector took a nose dive in 2Q...